A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Latest Information Update: 18 Sep 2024
At a glance
- Drugs Obefazimod (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Abivax
Most Recent Events
- 24 Jan 2023 Status changed from active, no longer recruiting to completed.
- 01 Jul 2022 This trial has been completed in Hungary according to European Clinical Trials Database record.
- 10 Mar 2022 Results presented in an Abivax media release.